Navigation Links
InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Date:3/5/2010

the safety and efficacy of pirfenidone in IPF patients on a number of clinical measures.  Prior to the CAPACITY results, data had previously been presented from another Phase 3 study and three Phase 2 clinical trials in more than 400 patients which suggested that pirfenidone may positively affect lung function and disease progression in patients with IPF.  In those clinical studies, pirfenidone was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.  In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi & Co. Ltd. in that country.

About IPF

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women.

About InterMune


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
2. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
3. InterMune to Present at Deutsche Bank Biotech Confab
4. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
5. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
6. InterMune to Present at JMP Securities Conference
7. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
8. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
9. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
10. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
11. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Inhibikase Therapeutics, Inc. today announced the election ... Directors of Inhibikase Therapeutics, Inc. ... Cubist Pharmaceuticals in 2008 and currently serves as ... and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, ...
... 2011 Codexis, Inc. (Nasdaq: CDXS ) today ... June.   The company will participate in the ... held in New York, NY on June 1-2, 2011. Alan ... a panel titled "Renewable Biomaterials", scheduled for June 1 at ...
Cached Medicine Technology:Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors 2Codexis to Present at 3 Investor Conferences in June 2
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... , , NEW YORK , Jan. ... information management industry leader, and Catalyst Repository Systems, Inc. ... for electronic discovery and regulatory compliance, jointly announced today ... legal document review market by offering ISO 9001:2008-certified Legal ...
... known that people who live or work in rural areas ... compared to those in more urban environments. But while time ... new research suggests that limited access to early, high-quality trauma ... Researchers from St. Michael,s in Toronto looked at 3,486 ...
... CITY University of Utah researchers led an international ... on the previously undescribed ability of platelets to reproduce ... online Jan. 19, 2010, in the journal Blood ... the bone marrow, a process that is called thrombopoiesis. ...
... , ... through Public Standards. , ... Rockville, MD (Vocus) January 26, 2010 -- The United States Pharmacopeial Convention (USP) ... Member delegates and experts from around the world will gather to discuss pressing global ...
... Celebrate ... ... and Oldways and the Mediterranean Foods Alliance offer 10 ways to ... Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean Diet is one ...
... up to $2,750, , TUESDAY, Jan. 26 (HealthDay News) -- ... banned from using a handheld device to send text messages, ... by the trucking and bus industry, goes into effect immediately, ... Secretary Ray LaHood said during a morning press conference. , ...
Cached Medicine News:Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 2Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 3Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 4Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 5Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 6Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Groundbreaking research shows platelets can reproduce in circulation 2Health News:Public Health in Focus at International Conference 2Health News:Public Health in Focus at International Conference 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3Health News:U.S. Bans Texting by Truck and Bus Drivers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: